By Sonja VanWye, RN, MSN, Director of Dermatology Strategy, IQVIA Biotech
How four data-driven protocol design analyses can increase chances of study success in dermatology clinical trials
Nearly 60 percent of clinical trials have protocol amendments,1 often required to address shortcomings in the study design, endpoints which do not support study objectives, excessive assessments which do not support study endpoints,2 or eligibility criteria. Such amendments are a major undertaking, leading to significant timeline delays and additional cost. It is imperative to understand the parts of a clinical trial protocol that could cause potential problems, proactively address them, and maximize the likelihood of study success.